Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Liver Diseases

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 57 articles:
HTML format



Single Articles


    February 2024
  1. SCHNABL B
    PPAR Agonists in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:855-858.
    PubMed    


  2. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
    A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:783-794.
    PubMed     Abstract available


  3. ASSIS DN
    Advancing Second-Line Treatment for Primary Biliary Cholangitis.
    N Engl J Med. 2024;390:853-854.
    PubMed    


  4. CUSI K
    Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.
    N Engl J Med. 2024;390:559-561.
    PubMed    


  5. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    PubMed     Abstract available


    December 2023
  6. CAI S, Kuang M
    Clonorchis sinensis Liver Flukes.
    N Engl J Med. 2023;389:e57.
    PubMed    


  7. LOOMBA R, Mansbach H, Margalit M
    Randomized Trial of Pegozafermin in NASH. Reply.
    N Engl J Med. 2023;389:2210.
    PubMed    


  8. PATOULIAS D
    Randomized Trial of Pegozafermin in NASH.
    N Engl J Med. 2023;389:2209-2210.
    PubMed    


    November 2023
  9. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    PubMed     Abstract available


  10. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    PubMed     Abstract available


    September 2023
  11. RINELLA ME
    Pegozafermin for NASH - A Sprint to Start a Marathon.
    N Engl J Med. 2023;389:1044-1046.
    PubMed    


  12. LOOMBA R, Sanyal AJ, Kowdley KV, Bhatt DL, et al
    Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
    N Engl J Med. 2023;389:998-1008.
    PubMed     Abstract available


  13. ROBERTS EA, Schilsky ML
    Current and Emerging Issues in Wilson's Disease.
    N Engl J Med. 2023;389:922-938.
    PubMed    


    August 2023
  14. VALLA DC, Garcia-Pagan JC
    Primary Budd-Chiari Syndrome. Reply.
    N Engl J Med. 2023;389:10.
    PubMed    


  15. BORSANI O, Pietra D, Rumi E
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;389:10.
    PubMed    


    July 2023
  16. DAUVILLIERS Y, Mignot E, Del Rio Villegas R, Du Y, et al
    Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
    N Engl J Med. 2023;389:309-321.
    PubMed     Abstract available


    June 2023
  17. BALWANI M, Desnick RJ, Belongie K
    Dersimelagon in Erythropoietic Protoporphyrias. Reply.
    N Engl J Med. 2023;388:2492-2493.
    PubMed    


  18. BARMAN-AKSOZEN J, Langendonk JG
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2492.
    PubMed    


  19. GRANATA F, Dechant C, Falchetto R
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:2491-2492.
    PubMed    


    April 2023
  20. BALWANI M, Bonkovsky HL, Levy C, Anderson KE, et al
    Dersimelagon in Erythropoietic Protoporphyrias.
    N Engl J Med. 2023;388:1376-1385.
    PubMed     Abstract available


  21. GARCIA-PAGAN JC, Valla DC
    Primary Budd-Chiari Syndrome.
    N Engl J Med. 2023;388:1307-1316.
    PubMed    


    February 2023
  22. NADIM MK, Garcia-Tsao G
    Acute Kidney Injury in Patients with Cirrhosis.
    N Engl J Med. 2023;388:733-745.
    PubMed    


  23. BHAN I, Schaefer EA, Bradley WR, Rodriguez-Lopez JM, et al
    Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing.
    N Engl J Med. 2023;388:544-554.
    PubMed    


  24. JU H, Liu C
    Cerebral Alveolar Echinococcosis.
    N Engl J Med. 2023;388:453.
    PubMed    


    January 2023
  25. GOYAL L, Meric-Bernstam F, Hollebecque A, Valle JW, et al
    Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
    N Engl J Med. 2023;388:228-239.
    PubMed     Abstract available


    December 2022
  26. VIEDMA-MARTINEZ M, Villegas Romero I
    Skin Necrosis after Transarterial Chemoembolization.
    N Engl J Med. 2022;387:2268.
    PubMed    


  27. OLYNYK JK, Ramm GA
    Hemochromatosis.
    N Engl J Med. 2022;387:2159-2170.
    PubMed    


    August 2022
  28. STRNAD P, Mandorfer M, Choudhury G, Griffiths W, et al
    Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
    N Engl J Med. 2022;387:514-524.
    PubMed     Abstract available


    July 2022
  29. VERWEIJ N, Haas ME, Nielsen JB, Sosina OA, et al
    Germline Mutations in CIDEB and Protection against Liver Disease.
    N Engl J Med. 2022;387:332-344.
    PubMed     Abstract available


    January 2022
  30. PATEL A, Tillman BF
    Spur-Cell Hemolytic Anemia.
    N Engl J Med. 2022;386:e6.
    PubMed    


  31. SANYAL AJ, Van Natta ML, Tonascia J
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:296.
    PubMed    


  32. FRANCQUE SM, Bedossa P, Abdelmalek MF
    Nonalcoholic Fatty Liver Disease. Reply.
    N Engl J Med. 2022;386:295-296.
    PubMed    


  33. MIR BA, Majeed T, Chauhan A
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:295.
    PubMed    


  34. XIA ML, Wang H
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294-295.
    PubMed    


  35. HORN P, Newsome PN
    Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2022;386:294.
    PubMed    


    December 2021
  36. WILLETT LL, Bromberg GK, Chung R, Leaf RK, et al
    Case 38-2021: A 76-Year-Old Woman with Abdominal Pain, Weight Loss, and Memory Impairment.
    N Engl J Med. 2021;385:2378-2388.
    PubMed    


    November 2021
  37. CHAPMAN MM, Muse VV, Mojica JE, Anahtar MN, et al
    Case 35-2021: A 50-Year-Old Woman with Pain in the Left Upper Quadrant and Hypoxemia.
    N Engl J Med. 2021;385:1995-2001.
    PubMed    


    October 2021
  38. GARCIA-TSAO G
    Nonalcoholic Steatohepatitis - Opportunities and Challenges.
    N Engl J Med. 2021;385:1615-1617.
    PubMed    


  39. SANYAL AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, et al
    Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2021;385:1559-1569.
    PubMed     Abstract available


  40. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021;385:1547-1558.
    PubMed     Abstract available


    September 2021
  41. CHANDRA A, Bhattacharjee MS
    Kayser-Fleischer Rings in Wilson's Disease.
    N Engl J Med. 2021;385:e46.
    PubMed    


  42. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis. Reply.
    N Engl J Med. 2021;385:1151-1152.
    PubMed    


  43. HAIDAR G, Singh N
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;385:1150-1151.
    PubMed    


    August 2021
  44. ZOU Q, Li Y
    Hypervirulent Klebsiella pneumoniae.
    N Engl J Med. 2021;385:833.
    PubMed    


  45. FREDRICK TW, Neto MBB, Johnsrud DO, Camilleri M, et al
    Turning Purple with Pain.
    N Engl J Med. 2021;385:549-554.
    PubMed    


    July 2021
  46. KELLEY RK, Greten TF
    Hepatocellular Carcinoma - Origins and Outcomes.
    N Engl J Med. 2021;385:280-282.
    PubMed    


  47. BUTTERS CT, Nash M
    Infantile Hepatic Hemangiomas.
    N Engl J Med. 2021;385:e10.
    PubMed    


  48. NEWSOME PN, Sejling AS, Sanyal AJ
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply.
    N Engl J Med. 2021;385:e6.
    PubMed    


  49. DA BL, Satapathy SK
    Semaglutide or Placebo for Nonalcoholic Steatohepatitis.
    N Engl J Med. 2021;385:e6.
    PubMed    


    June 2021
  50. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;384:2317-2330.
    PubMed    


  51. WONG F, Curry MP, Sanyal AJ
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    


  52. CHINA L, Freemantle N, O'Brien A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    


  53. RATHI S, Kalantri A, Kalantri S
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    


  54. CHAUHAN A, Sharma S, Saraya A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    


  55. ELFEKI MA, O'Shea R, Carey WD
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    


    April 2021
  56. COHN A, Nehs M, Chan J, Vaidya A, et al
    Casting a Wide Net.
    N Engl J Med. 2021;384:e50.
    PubMed    


  57. MCINNES IB, Anderson JK, Magrey M, Merola JF, et al
    Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    N Engl J Med. 2021;384:1227-1239.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.